Cargando…

Association of FCGR3A and FCGR3B Copy Number Variations With Systemic Lupus Erythematosus and Rheumatoid Arthritis in Taiwanese Patients

OBJECTIVE: To determine whether copy number variations (CNVs) in FCGR3A and FCGR3B are associated with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Taiwanese individuals. METHODS: FCGR3A and FCGR3B CNV genotypes were determined in 846 patients with SLE, 948 patients with RA, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ji-Yih, Wang, Chin-Man, Chang, Su-Wei, Cheng, Ching-Hui, Wu, Yeong-Jian Jan, Lin, Jing-Chi, Yang, Bing, Ho, Huei-Huang, Wu, Jianming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Systemic Lupus Erythematosus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232894/ https://www.ncbi.nlm.nih.gov/pubmed/25154742 http://dx.doi.org/10.1002/art.38813

Ejemplares similares

3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
por: Zhao, Ming, et al.
Publicado: (2023)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2016)

Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity
por: Kim, Alfred H. J., et al.
Publicado: (2019)

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
por: van Vollenhoven, Ronald F, et al.
Publicado: (2022)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Genomic sequencing and functional analyses identify MAP4K3/GLK germline and somatic variants associated with systemic lupus erythematosus
por: Chuang, Huai-Chia, et al.
Publicado: (2022)

Association of Systemic Lupus Erythematosus With Decreased Immunosuppressive Potential of the IgG Glycome
por: Vučković, Frano, et al.
Publicado: (2015)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

A CD8 T Cell/Indoleamine 2,3-Dioxygenase Axis Is Required for Mesenchymal Stem Cell Suppression of Human Systemic Lupus Erythematosus
por: Wang, Dandan, et al.
Publicado: (2014)

Arg206Cys substitution in DNASE1L3 causes a defect in DNASE1L3 protein secretion that confers risk of systemic lupus erythematosus
por: Coke, Latanya N, et al.
Publicado: (2021)

Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus
por: Yin, Xianyong, et al.
Publicado: (2021)

Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus
por: Grigoriou, Maria, et al.
Publicado: (2020)

Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing
por: Sandling, Johanna K, et al.
Publicado: (2021)

Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study
por: Tian, Jingru, et al.
Publicado: (2023)

Dietary Omega Polyunsaturated Fatty Acid Intake and Patient‐Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program
por: Charoenwoodhipong, Prae, et al.
Publicado: (2020)

Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study
por: Yin, Xianyong, et al.
Publicado: (2022)

Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes
por: Barraclough, Michelle, et al.
Publicado: (2019)

Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
por: Groot, N., et al.
Publicado: (2019)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long‐Term Effects on Serum Immunoglobulins
por: Reddy, Venkat, et al.
Publicado: (2017)

Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus
por: Adamichou, Christina, et al.
Publicado: (2021)

Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus
por: Rahman, Saifur, et al.
Publicado: (2019)

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
por: Wallace, Daniel J., et al.
Publicado: (2019)

Dynamics of Methylation of CpG Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort
por: Lanata, Cristina M., et al.
Publicado: (2022)

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese
por: Tomofuji, Yoshihiko, et al.
Publicado: (2021)

Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision‐Making in Systemic Lupus Erythematosus Treatment?
por: Almeida‐Brasil, Celline C., et al.
Publicado: (2022)

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
por: Hasni, Sarfaraz, et al.
Publicado: (2022)

Patient Experiences of Systemic Lupus Erythematosus: Findings From a Systematic Review, Meta‐Summary, and Meta‐Synthesis
por: Petrocchi, Valentina, et al.
Publicado: (2022)

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
por: Brunner, Hermine I, et al.
Publicado: (2020)

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus
por: Reid, Sarah, et al.
Publicado: (2020)

Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus
por: Cesaroni, Matteo, et al.
Publicado: (2021)

Brief Report: A Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled, Multiple‐Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis
por: Cheng, Laurence E., et al.
Publicado: (2018)

Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus
por: Welcher, Andrew A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_47os2itsl0o2oougrm2opdbp75